Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding CD33 or an epitope of CD33 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.
Type:
Application
Filed:
June 5, 2020
Publication date:
October 13, 2022
Applicant:
Mythic Therapeutics, Inc.
Inventors:
Alexander J. Nichols, Brian P. Fiske, Nimish Gera
Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding DLL3 or an epitope of DLL3 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.
Type:
Application
Filed:
June 5, 2020
Publication date:
October 6, 2022
Applicant:
Mythic Therapeutics, Inc.
Inventors:
Alexander J. Nichols, Brian P. Fiske, Nimish Gera
Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding FOLR1 or an epitope of FOLR1 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.
Type:
Application
Filed:
June 5, 2020
Publication date:
September 22, 2022
Applicant:
Mythic Therapeutics, Inc.
Inventors:
Alexander J. Nichols, Brian P. Fiske, Nimish Gera
Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding CD22 or an epitope of CD22 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.
Type:
Application
Filed:
July 8, 2020
Publication date:
September 15, 2022
Applicant:
Mythic Therapeutics, Inc.
Inventors:
Alexander J. Nichols, Brian P. Fiske, Nimish Gera
Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding MET or an epitope of MET presented on surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.
Type:
Application
Filed:
July 30, 2020
Publication date:
September 8, 2022
Applicant:
Mythic Therapeutics, Inc.
Inventors:
Alexander J. Nichols, Brian P. Fiske, Nimish Gera